Business Context and Reporting Period
Company: CorMedix Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 14, 2019
Event: Entry into a Material Definitive Agreement (Securities Exchange Agreement) with Elliott Associates, L.P., Elliott International, L.P., and Manchester Securities Corp. (collectively "Elliott"), the Company's largest investor.
Key Financial Metrics and Transaction Details
This filing details a capital restructuring transaction rather than standard operating financial results. Key metrics related to the transaction include:
- Cash Payment: $2,000,000 paid by the Company to Elliott.
- Securities Surrendered:
- Series C-2, Series D, and Series F Preferred Stock (convertible into 3,064,985 shares of Common Stock).
- Warrants (right to purchase 892,972 shares of Common Stock).
- 10% Senior Secured Convertible Notes (Principal: $7,879,688; Accrued Interest: $379,688; convertible into 1,059,812 shares).
- Series E Warrants (40,000 shares) cancelled without issuance of new preferred stock.
- Securities Issued: 100,000 shares of new Series G Preferred Stock.
- Liquidation Preference: Aggregate of $18,736,452 for Series G Preferred Stock.
- Conversion Terms: Series G is convertible into up to 5,560,138 shares of Common Stock at $3.37 per share.
- Ownership Cap: Elliott is prohibited from converting if it would own more than 4.99% of outstanding Common Stock.
Note: The filing does not provide revenue, profit, cash flow, or margin data for the reporting period.
Material Changes and Transaction Mechanics
The transaction resolves all issues relating to the surrendered securities through a mutual release. Material changes include:
- Debt Restructuring: Conversion of approximately $8.26 million in principal and accrued interest of Senior Secured Convertible Notes into equity (Series G Preferred Stock).
- Preferred Stock Hierarchy: Series G Preferred Stock ranks pari passu with Series C-3 and Series E Preferred Stock regarding liquidation preferences, subject to necessary consents.
- Clawback Provision: If the Common Stock trades at or above $11.25 for 20 trading days within a 30-day period within 18 months of issuance, up to 2,513 shares of Series G Preferred Stock (representing 139,769 Common shares) will be automatically cancelled.
- Voting Rights: Series G and amended Series E Preferred Stock will vote on an as-converted basis based on the closing price of Common Stock on August 14, 2019.
Outlook, Risks, and Management Commentary
- Use of Proceeds: The $2,000,000 cash payment is funded by the Company; the transaction is intended to provide working capital and fund capital expenditures.
- Closing Date: Anticipated on or prior to September 15, 2019, subject to customary conditions.
- Board Approval: A Special Committee of independent directors, after consulting financial advisors, determined the agreement is in the best interests of the Company.
- Risks and Contingencies:
- The Series G Preferred Stock is unregistered and relies on private placement exemptions (Section 4(a)(2) and Rule 506(b)).
- Subordination of Series C-3 Preferred Stock to Series G requires consent from Series C-3 holders.
- Representations and warranties in the agreement are qualified and should not be relied upon as characterizations of the Company's actual state of facts.
Investor Verification Checklist
- Verify the final closing date of the transaction (expected by September 15, 2019).
- Confirm receipt of necessary consents from Series C-3 Preferred Stock holders regarding subordination.
- Monitor the Common Stock trading price for the $11.25 threshold that triggers the automatic cancellation (clawback) of Series G shares.
- Review the full text of the Securities Exchange Agreement (Exhibit 10.1) for detailed restrictive covenants and representations.
- Check for subsequent filings regarding the amendment of the Registration Rights Agreement to include the new securities.